Navigation Links
IDRI Develops Novel Tuberculosis Vaccine, New Study in Science Reports

SEATTLE, Oct. 16 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) announces it has developed a new tuberculosis (TB) vaccine that protects against TB including drug-resistant strains of the disease in animal studies. The results of these studies are published in Science Translational Medicine today.

Drug-resistant tuberculosis is a major global public health concern. According to the World Health Organization, approximately 9 million people are infected with TB, and close to half a million are resistant to multiple drugs that once effectively treated the disease. Two million people die of TB each year.

Though a childhood vaccine for tuberculosis, BCG, has been widely used for decades, its protection wanes over time, and new virulent forms of the disease are spreading. Control activities are limited without new vaccines, immunotherapeutics, and drugs to protect against these killer strains of TB.

IDRI's TB vaccine enhances and extends BCG and protects against drug-resistant strains through its unique combination of a molecule containing four tuberculosis proteins with a synthetic adjuvant, also developed at IDRI.

Dr. Rhea Coler, Vice President of Preclinical Biology and one of the study's Principal Investigators, explains, "Combining proteins in a vaccine is important because tuberculosis bacilli are variable, and no single protein will be effective against all strains."  In addition, because of human genetic diversity, individuals will respond differently to different proteins. A combination of proteins, such as exist in natural tuberculosis bacteria, increases the vaccine's efficacy.

The vaccine is now being developed for clinical testing in humans.

About IDRI – Translating science into global health solutions

IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty. By integrating capabilities—including preclinical vaccinology, manufacturing, and clinical trials—IDRI strives to create an efficient pathway bringing scientific innovation from the lab to the people who need it most.

For more information, go to  

SOURCE Infectious Disease Research Institute (IDRI)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
2. Nventa Develops Proprietary Vaccine Adjuvant
3. Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
4. Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures
5. Binghamton Research Group Develops New Cancer Treatment
6. Saft Develops Super-Phosphate(TM) Technology for Rigorous Defense Applications
7. Panel of Osteoarthritis Experts Develops Optimal Profile of Exogenous Hyaluronic Acid
8. HDT Develops Robotic Arm Technology for DARPAs Revolutionizing Prosthetics 2009 Program
9. Solos Endoscopy, Inc. Develops Relay Lense Adapter System For MammoView® Product Line
10. PharmAthene Develops Thermostable Lyophilized rPA Anthrax Vaccine Under a Challenge Grant From the National Institutes of Health
11. Varian Medical Systems Develops New X-Ray Tube for Use in Security Scanning Systems
Post Your Comments:
(Date:10/13/2015)...  Vitamin Angels – a charity that distributes vitamins ... nutritional support - announced its work continues to support ... The UN,s newly established Global Goals - announced on ... up to the Millennium Development Goals established in 2000 ... 17 Global Goals intend to address three primary objectives: ...
(Date:10/13/2015)... -- A minimally-invasive treatment just became available to men suffering ... than 10 years of clinical trials, the Food and ... High Intensity Focused Ultrasound (HIFU), a procedure that can ... and minimizing chances for erectile and urinary dysfunction associated ... pioneering Miami urologist who spearheaded ...
(Date:10/13/2015)... 13, 2015  ContraVir Pharmaceuticals, Inc. (Nasdaq: ... company focused on the development and commercialization of ... its previously announced underwritten public offering of 5,000,000 ... purchase up to 3,000,000 shares of the Company,s ... the public of $3.00. The shares of common ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 2015 , ... Sir Grout of Greater Boston donated an expansive, seven room ... McDonald House Charities® (RMHC®). This donation was made in an effort to give back ... its inception. , “We believe strongly in the Ronald McDonald House Charities, and they ...
(Date:10/13/2015)... Diego, CA (PRWEB) , ... October 13, 2015 ... ... launch of its newest technology platform, ENGAGE, at HIMSS’s Patient Engagement Summit ... to end. , ENGAGE delivers innovative health programs and interventions via mobile devices ...
(Date:10/13/2015)... ... 2015 , ... Element Blue ™, a leading IT ... RightSensor™ LLC, an Internet of Things (IoT) hardware supplier that delivers custom and ... for customers requiring sensor hardware for critical data environments. , RightSensor™, working with ...
(Date:10/13/2015)... ... October 13, 2015 , ... NavaFit Inc. today announced the launch of its ... with, participate in local fitness & sporting events, and stay motivated. Users ... medical costs drive us to get more serious about fitness and wellness, individuals are ...
(Date:10/13/2015)... (PRWEB) , ... October 13, ... ... Postnatal Omega-3, a first-of-its kind product that targets the unique health needs ... Omega-3” of the American Pregnancy Association ( ), utilizes Nordic Naturals’ ...
Breaking Medicine News(10 mins):